Kezar Life Sciences, Inc.
KZRNASDAQHealthcare
$7.29
+$0.00(+0.00%)
Market Cap$53856333
P/E Ratio—
52W High$7.55
52W Low$3.53
Kezar Life Sciences, Inc. (KZR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KZR · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.78
Est. -$0.98 · +20.4%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
KZR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$1.05 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.98 | -$0.78 | +20.4% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 27, 2026 | -$1.31 | -$1.99 | -52.0% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$1.81 | -$1.53 | +15.5% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$2.15 | -$1.87 | +13.0% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$2.56 | -$2.27 | +11.3% | — | — | — |
| ▼ Q1 FY2025 | Mar 25, 2025 | -$2.71 | -$2.77 | -2.2% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$3.03 | -$2.78 | +8.3% | — | $0.00B | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$1.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.78
EPS Est.
-$0.98
EPS Surpr.
+20.4%
Revenue
—
Q1 FY2026
Mar 27, 2026Miss
EPS Actual
-$1.99
EPS Est.
-$1.31
EPS Surpr.
-52.0%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$1.53
EPS Est.
-$1.81
EPS Surpr.
+15.5%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$1.87
EPS Est.
-$2.15
EPS Surpr.
+13.0%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$2.27
EPS Est.
-$2.56
EPS Surpr.
+11.3%
Revenue
—
Q1 FY2025
Mar 25, 2025Miss
EPS Actual
-$2.77
EPS Est.
-$2.71
EPS Surpr.
-2.2%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$2.78
EPS Est.
-$3.03
EPS Surpr.
+8.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.68 | $-0.68 | $-0.68 | 1 |
| Q3 FY2028 | $-0.75 | $-0.75 | $-0.75 | 1 |
| Q2 FY2028 | $-0.81 | $-0.81 | $-0.81 | 1 |
| Q1 FY2028 | $-0.82 | $-0.82 | $-0.82 | 1 |
| Q4 FY2027 | $-0.82 | $-0.82 | $-0.82 | 1 |
| Q3 FY2027 | $-0.82 | $-0.82 | $-0.82 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +20.4% | $7.29 | $7.29 | +0.00% |
| ▼ Q1 FY2026 | Mar 27, 2026 | -52.0% | $6.35 | $6.20 | -2.36% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +15.5% | $6.18 | $6.16 | -0.32% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +13.0% | $3.90 | $3.92 | +0.51% |
| ▲ Q2 FY2025 | May 13, 2025 | +11.3% | $4.23 | $4.20 | -0.71% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -2.2% | $6.16 | $5.64 | -8.44% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +8.3% | $7.44 | $7.49 | +0.67% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +12.5% | $59.10 | $58.00 | -1.86% |
Q2 FY2026+0.00%
Report Date
May 11, 2026
EPS Beat/Miss
+20.4%
Price Before
$7.29
Price After
$7.29
Q1 FY2026-2.36%
Report Date
Mar 27, 2026
EPS Beat/Miss
-52.0%
Price Before
$6.35
Price After
$6.20
Q4 FY2025-0.32%
Report Date
Nov 12, 2025
EPS Beat/Miss
+15.5%
Price Before
$6.18
Price After
$6.16
Q3 FY2025+0.51%
Report Date
Aug 13, 2025
EPS Beat/Miss
+13.0%
Price Before
$3.90
Price After
$3.92
Q2 FY2025-0.71%
Report Date
May 13, 2025
EPS Beat/Miss
+11.3%
Price Before
$4.23
Price After
$4.20
Q1 FY2025-8.44%
Report Date
Mar 25, 2025
EPS Beat/Miss
-2.2%
Price Before
$6.16
Price After
$5.64
Q4 FY2024+0.67%
Report Date
Nov 12, 2024
EPS Beat/Miss
+8.3%
Price Before
$7.44
Price After
$7.49
Q3 FY2024-1.86%
Report Date
Aug 13, 2024
EPS Beat/Miss
+12.5%
Price Before
$59.10
Price After
$58.00
Avg Beat Reaction-0.28%
Avg Miss Reaction-5.40%
Beat Rate6 / 8 quarters
Largest Move-8.44% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KZR ends December
Kezar Life Sciences, Inc. (KZR) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.78 — beating the analyst consensus of $-0.98 by +20.4%. The next KZR earnings date is expected around September 1, 2026.
Each quarter, investors track KZR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KZR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KZR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KZR earnings · 5 questionsKezar Life Sciences, Inc.'s next earnings report is expected around September 1, 2026. KZR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KZR historically reports after market close (AMC).
KZR earnings datewhen is KZR earningsKZR next earnings datewhen does KZR report earningsKZR earnings calendar
▸ Source: FMP · Kezar Life Sciences, Inc. SEC filings · US GAAP · Kezar Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026